These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 23273822)

  • 1. Advanced Hepatocellular Carcinoma: early evaluation of response to targeted therapy and prognostic value of Perfusion CT and Dynamic Contrast Enhanced-Ultrasound. Preliminary results.
    Frampas E; Lassau N; Zappa M; Vullierme MP; Koscielny S; Vilgrain V
    Eur J Radiol; 2013 May; 82(5):e205-11. PubMed ID: 23273822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US.
    Sugimoto K; Moriyasu F; Saito K; Rognin N; Kamiyama N; Furuichi Y; Imai Y
    Liver Int; 2013 Apr; 33(4):605-15. PubMed ID: 23305331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring response to antiangiogenic treatment and predicting outcomes in advanced hepatocellular carcinoma using image biomarkers, CT perfusion, tumor density, and tumor size (RECIST).
    Jiang T; Kambadakone A; Kulkarni NM; Zhu AX; Sahani DV
    Invest Radiol; 2012 Jan; 47(1):11-7. PubMed ID: 21512396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma: the role of dynamic contrast enhanced ultrasound.
    Zocco MA; Garcovich M; Lupascu A; Di Stasio E; Roccarina D; Annicchiarico BE; Riccardi L; Ainora ME; Ponziani F; Caracciolo G; Rapaccini GL; Landolfi R; Siciliano M; Pompili M; Gasbarrini A
    J Hepatol; 2013 Nov; 59(5):1014-21. PubMed ID: 23811306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advanced hepatocellular carcinoma: early evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US with quantification--preliminary results.
    Lassau N; Koscielny S; Chami L; Chebil M; Benatsou B; Roche A; Ducreux M; Malka D; Boige V
    Radiology; 2011 Jan; 258(1):291-300. PubMed ID: 20980447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, Choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma.
    Krajewski KM; Guo M; Van den Abbeele AD; Yap J; Ramaiya N; Jagannathan J; Heng DY; Atkins MB; McDermott DF; Schutz FA; Pedrosa I; Choueiri TK
    Eur Urol; 2011 May; 59(5):856-62. PubMed ID: 21306819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility of Using Volumetric Contrast-Enhanced Ultrasound with a 3-D Transducer to Evaluate Therapeutic Response after Targeted Therapy in Rabbit Hepatic VX2 Carcinoma.
    Kim J; Kim JH; Yoon SH; Choi WS; Kim YJ; Han JK; Choi BI
    Ultrasound Med Biol; 2015 Dec; 41(12):3131-9. PubMed ID: 26365926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of perfusion CT in hepatocellular carcinoma treatment with sorafenib: comparison with mRECIST in longitudinal follow-up.
    Kaufmann S; Thaiss WM; Schulze M; Bitzer M; Lauer U; Nikolaou K; Horger M
    Acta Radiol; 2018 Jul; 59(7):765-772. PubMed ID: 28927298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib.
    Faivre S; Zappa M; Vilgrain V; Boucher E; Douillard JY; Lim HY; Kim JS; Im SA; Kang YK; Bouattour M; Dokmak S; Dreyer C; Sablin MP; Serrate C; Cheng AL; Lanzalone S; Lin X; Lechuga MJ; Raymond E
    Clin Cancer Res; 2011 Jul; 17(13):4504-12. PubMed ID: 21531821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of response to sorafenib in advanced hepatocellular carcinoma using perfusion computed tomography: results of a pilot study.
    Sacco R; Faggioni L; Bargellini I; Ginanni B; Battaglia V; Romano A; Bertini M; Bresci G; Bartolozzi C
    Dig Liver Dis; 2013 Sep; 45(9):776-81. PubMed ID: 23578581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantitative therapy response assessment by volumetric iodine-uptake measurement: initial experience in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Dai X; Schlemmer HP; Schmidt B; Höh K; Xu K; Ganten TM; Ganten MK
    Eur J Radiol; 2013 Feb; 82(2):327-34. PubMed ID: 23246016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early response to anti-tumoral treatment in hepatocellular carcinoma--can quantitative contrast-enhanced ultrasound predict outcome?
    Knieling F; Waldner MJ; Goertz RS; Zopf S; Wildner D; Neurath MF; Bernatik T; Strobel D
    Ultraschall Med; 2013 Feb; 34(1):38-46. PubMed ID: 23258770
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intermediate and advanced hepatocellular carcinoma treated with the antiangiogenic agent sorafenib. Evaluation with unenhanced and contrast-enhanced ultrasonography.
    Moschouris H; Malagari K; Gkoutzios P; Kalokairinou M; Stamatiou K; Chatzimichail K; Kornezos I; Karagiannis E; Kiltenis M; Papadaki MG
    Med Ultrason; 2012 Jun; 14(2):87-94. PubMed ID: 22675707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatocellular carcinoma treated with sorafenib: Arterial tumor perfusion in dynamic contrast-enhanced CT as early imaging biomarkers for survival.
    Nakamura Y; Kawaoka T; Higaki T; Fukumoto W; Honda Y; Iida M; Fujioka C; Kiguchi M; Aikata H; Chayama K; Awai K
    Eur J Radiol; 2018 Jan; 98():41-49. PubMed ID: 29279169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dynamic contrast-enhanced ultrasound (DCE-US) for easy and rapid evaluation of hepatocellular carcinoma compared to dynamic contrast-enhanced computed tomography (DCE-CT)--a pilot study.
    Egger C; Goertz RS; Strobel D; Lell M; Neurath MF; Knieling F; Scharf M
    Ultraschall Med; 2012 Dec; 33(6):587-92. PubMed ID: 23154871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis.
    Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
    Urol Oncol; 2013 Oct; 31(7):1283-91. PubMed ID: 21956044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT.
    Fournier LS; Oudard S; Thiam R; Trinquart L; Banu E; Medioni J; Balvay D; Chatellier G; Frija G; Cuenod CA
    Radiology; 2010 Aug; 256(2):511-8. PubMed ID: 20551183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of sorafenib for hepatocellular carcinoma by contrast-enhanced ultrasonography: a pilot study.
    Shiozawa K; Watanabe M; Kikuchi Y; Kudo T; Maruyama K; Sumino Y
    World J Gastroenterol; 2012 Oct; 18(40):5753-8. PubMed ID: 23155317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.
    Edeline J; Boucher E; Rolland Y; Vauléon E; Pracht M; Perrin C; Le Roux C; Raoul JL
    Cancer; 2012 Jan; 118(1):147-56. PubMed ID: 21713764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic value of dynamic contrast-enhanced CT with perfusion imaging in the quantitative assessment of tumor response to sorafenib in patients with advanced hepatocellular carcinoma: A feasibility study.
    Ippolito D; Querques G; Okolicsanyi S; Franzesi CT; Strazzabosco M; Sironi S
    Eur J Radiol; 2017 May; 90():34-41. PubMed ID: 28583645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.